PMV Pharmaceuticals, Inc. – NASDAQ:PMVP

Add to watchlist

$1.579

+0.07

+5.29%

Market open

Closed in about 5 hours

-5.06%

month

-5.06%

quarter

-53.99%

year

Market Cap	75.80M
Enterprise value	90.03M

P/E	-2.87
EV/Sales	N/A
EV/EBITDA	-1.23
Price/Sales	N/A
Price/Book	0.74
PEG ratio	0.10
EPS	-1.33

Revenue	N/A
EBITDA	-75.78M
Income	-65.10M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

PMV Pharmaceuticals Stock Forecast

M Q Y

Last Year

Potential upside: 279.91%

Analysts Price target
Financials & Ratios estimates

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP): Profit margin
Jun 2023	0	-17.43M
Sep 2023	0	-16.64M
Dec 2023	1.61M	-15.75M	-973.79%
Mar 2024	0	-15.27M

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP): Debt to assets
Jun 2023	242216000	24.40M	10.08%
Sep 2023	261027000	23.41M	8.97%
Dec 2023	252152000	26.46M	10.49%
Mar 2024	236876000	24.2M	10.22%

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP): Cash Flow
Jun 2023	-12.90M	-63.96M	2.13M
Sep 2023	-15.65M	-33.63M	33.14M
Dec 2023	-12.08M	-2.58M	288K
Mar 2024	-16.18M	26.16M	0

PMV Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP): Employee count
Aug 2023	62
Sep 2023	62
Oct 2023	62
Nov 2023	62
Dec 2023	62
Jan 2024	62
Feb 2024	62
Mar 2024	63
Apr 2024	63
May 2024	63
Jun 2024	63
Jul 2024	63

PMV Pharmaceuticals
Hedge Funds Holdings Q1 2023

51.08% -48.92%

of PMVP is owned by hedge funds

60 -53

hedge funds hold PMVP stock

23.28M -31.23M

shares is hold by hedge funds

PMVP hedge funds holdings changes

PMV Pharmaceuticals
Insider Trading

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP): Insider trades (number of shares)
Period	Buy	Sel
Sep 2023	0	10395
Nov 2023	0	87786

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	22 Nov 2023	ORBIMED ADVISORS LLC 10 percent owner 10 percent owner	Common Stock	87,786	$2.23	$195,763
Option	18 Oct 2023	MACK DAVID HENRY director, officer..	Common Stock	198,407	$0.53	$105,156
Sale	15 Sep 2023	JALOTA DEEPIKA officer: Chief Development Officer officer: Chief Development Offi..	Common Stock	4,104	$6.62	$27,168
Sale	15 Sep 2023	ALLAND LEILA officer: Chief Me..	Common Stock	6,291	$6.62	$41,646
Option	7 Aug 2023	MACK DAVID HENRY director, officer..	Employee Stock Option (right to buy)	85,500	$0.53	$45,315
Option	7 Aug 2023	MACK DAVID HENRY director, officer..	Common Stock	85,500	$0.53	$45,315
Sale	26 May 2022	ORBIMED ADVISORS LLC 10 percent owner 10 percent owner	Common Stock	26,253	$15.93	$418,210
Option	27 Apr 2022	MACK DAVID HENRY director, officer..	Employee Stock Option (right to buy)	33,000	$0.53	$17,490
Option	27 Apr 2022	MACK DAVID HENRY director, officer..	Common Stock	33,000	$0.53	$17,490
Option	20 Apr 2022	KUNG WINSTON officer: COO, CFO	Stock Option (right to buy)	4,000	$3.22	$12,880

PMVP insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION Filling date: 24 Feb 2022 Issue date: 7 Jul 2022	24 Feb 2022	7 Jul 2022
Application	Application COMPOSITIONS AND METHODS UTILIZING GENETICALLY-MODIFIED ANIMALS AND CELLS Filling date: 24 Jun 2021 Issue date: 30 Dec 2021	24 Jun 2021	30 Dec 2021
Application	Application METHODS FOR DETECTING MUTANT P53 FUNCTION Filling date: 22 Jun 2021 Issue date: 30 Dec 2021	22 Jun 2021	30 Dec 2021
Application	Application METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION Filling date: 16 Mar 2020 Issue date: 7 Jan 2021	16 Mar 2020	7 Jan 2021

PMV Pharmaceuticals
Executives

Insider	Age	Compensation
Dr. David H. Mack Ph.D. (1962) Co-Founder, Chief Executive Officer, Pres & Director	63	$770,330
Dr. Leila Alland M.D. (1962) Chief Medical Officer	63	$629,670
Mr. Winston Kung (1976) Chief Operating Officer & Chief Financial Officer	49	$608,930
Dr. Arnold J. Levine Ph.D. (1940) Co-Founder, Independent Director & Member of Scientific Advisory Board	85	$110,000

PMV Pharmaceuticals
Latest News

Monday, 3 June 2024
10:56	Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher	zacks.com
Wednesday, 29 May 2024
07:00	Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	globenewswire.com
07:00	Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	businesswire.com
Thursday, 9 May 2024
08:00	PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights	globenewswire.com
Wednesday, 27 March 2024
08:00	PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors	globenewswire.com
Monday, 18 March 2024
16:01	PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer	globenewswire.com
Thursday, 29 February 2024
16:01	PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights	globenewswire.com
Monday, 16 October 2023
11:18	PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner	Zacks Investment Research
Wednesday, 11 October 2023
12:00	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar	GlobeNewsWire
Wednesday, 20 September 2023
16:05	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	GlobeNewsWire
Wednesday, 30 August 2023
11:16	Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet	Zacks Investment Research
Tuesday, 6 June 2023
16:01	PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference	GlobeNewsWire
Wednesday, 30 November 2022
11:18	Top 10 most-shorted stocks as of November 2022	Finbold
Tuesday, 11 October 2022
13:32	PMV Pharmaceuticals, Inc. (PMVP) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research
Wednesday, 8 June 2022
08:00	PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference	GlobeNewsWire
Tuesday, 7 June 2022
13:00	Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday	InvestorPlace
Wednesday, 27 April 2022
10:30	PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	GlobeNewsWire
Monday, 22 November 2021
08:00	PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference	GlobeNewsWire
Thursday, 2 September 2021
08:00	PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference	GlobeNewsWire
Friday, 13 August 2021
08:00	PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 14 Nov 2023

PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price
Seeking Alpha 30 Aug 2023

PMV Pharmaceuticals: A 5-Month Run-Up Is Justified

Frequently Asked Questions (FAQ)

What's the price of PMV Pharmaceuticals stock today?

One share of PMV Pharmaceuticals stock can currently be purchased for approximately $1.58.
When is PMV Pharmaceuticals's next earnings date?

Unfortunately, PMV Pharmaceuticals's (PMVP) next earnings date is currently unknown.
Does PMV Pharmaceuticals pay dividends?

No, PMV Pharmaceuticals does not pay dividends.
How much money does PMV Pharmaceuticals make?

PMV Pharmaceuticals has a market capitalization of 75.80M.
What is PMV Pharmaceuticals's stock symbol?

PMV Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PMVP".
What is PMV Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of PMV Pharmaceuticals?

Shares of PMV Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are PMV Pharmaceuticals's key executives?
PMV Pharmaceuticals's management team includes the following people:
- Dr. David H. Mack Ph.D. Co-Founder, Chief Executive Officer, Pres & Director(age: 63, pay: $770,330)
- Dr. Leila Alland M.D. Chief Medical Officer(age: 63, pay: $629,670)
- Mr. Winston Kung Chief Operating Officer & Chief Financial Officer(age: 49, pay: $608,930)
- Dr. Arnold J. Levine Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board(age: 85, pay: $110,000)
Is PMV Pharmaceuticals founder-led company?

Yes, PMV Pharmaceuticals is a company led by its founders Dr. David H. Mack Ph.D. and Dr. Arnold J. Levine Ph.D..
How many employees does PMV Pharmaceuticals have?

As Jul 2024, PMV Pharmaceuticals employs 63 workers.
When PMV Pharmaceuticals went public?

PMV Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 25 Sep 2020.
What is PMV Pharmaceuticals's official website?

The official website for PMV Pharmaceuticals is pmvpharma.com.
Where are PMV Pharmaceuticals's headquarters?

PMV Pharmaceuticals is headquartered at 8 Clarke Drive, Cranbury, NJ.
How can i contact PMV Pharmaceuticals?

PMV Pharmaceuticals's mailing address is 8 Clarke Drive, Cranbury, NJ and company can be reached via phone at +60 9 642 6670.
What is PMV Pharmaceuticals stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for PMV Pharmaceuticals in the last 12 months, the avarage price target is $6. The average price target represents a 279.91% change from the last price of $1.58.

PMV Pharmaceuticals, Inc.

pmvpharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

+60 9 642 6670

8 Clarke Drive
Cranbury, NJ 08512

CIK: 0001699382
ISIN: US69353Y1038
CUSIP: 69353Y103